These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4595485)

  • 1. The metabolic effects, and the composition of the tissue lost, in weight reduction by obese patients on treatment with fenfluramine.
    Durnin JV; Womersley J
    Br J Pharmacol; 1973 Sep; 49(1):115-20. PubMed ID: 4595485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with fenfluramine in obese subjects.
    Sensi S; Della Loggia F; Del Ponte A; Guagnano MT
    Int J Clin Pharmacol Res; 1985; 5(4):247-53. PubMed ID: 4055167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Is it possible to obtain a reduction of body weight exclusively via a loss in fat mass? Experience with d-fenfluramine].
    Del Ponte A; D'Orazio N; Di Giacomo G; Tritella T; Bitti G; Martines G
    Recenti Prog Med; 1993 Feb; 84(2):100-5. PubMed ID: 8465086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled investigation of the "glycolyptic" action of fenfluramine.
    Garrow JS; Belton EA; Daniels A
    Lancet; 1972 Sep; 2(7777):559-61. PubMed ID: 4115737
    [No Abstract]   [Full Text] [Related]  

  • 5. Fenfluramine, vitamin C and weight loss.
    Wilson CW; Foran K; Innes JA; Watson ML; Ford MJ; Stoddart ME; Munro JF
    Int J Obes; 1978; 2(4):463-5. PubMed ID: 370042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction.
    Van Gaal LF; Vansant GA; Steijaert MC; De Leeuw IH
    Metabolism; 1995 Feb; 44(2 Suppl 2):42-5. PubMed ID: 7869937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects and anti-obesity action of fenfluramine in prolonged-acting form.
    Ranquin R; Brems HM
    Curr Med Res Opin; 1977-1978; 5(4):341-6. PubMed ID: 630909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects of fenfluramine--a double-blind study.
    Petrie JC; Mowat JA; Bewsher PD; Stowers JM
    Postgrad Med J; 1975; 51 Suppl 1():139-44. PubMed ID: 768954
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term efficacy of fenfluramine in treatment of obesity.
    Douglas JG; Gough J; Preston PG; Frazer I; Haslett C; Chalmers SR; Munro JF
    Lancet; 1983 Feb; 1(8321):384-6. PubMed ID: 6130379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of caloric restriction and fenfluramine on weight loss and personality profiles of patients with long standing obesity.
    Goldrick RB; Havenstein N; Whyte HM
    Aust N Z J Med; 1973 Apr; 3(2):131-41. PubMed ID: 4146050
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulatory effects of fenfluramine in obese hypertensive patients.
    Mroczek WJ; Lee WR; Finnerty FA
    Curr Ther Res Clin Exp; 1974 Nov; 16(11):1197-202. PubMed ID: 4214654
    [No Abstract]   [Full Text] [Related]  

  • 12. Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine.
    Rickels K; Hesbacher P; Fisher E; Perloff MM; Rosenfeld H
    Psychol Med; 1976 Nov; 6(4):623-30. PubMed ID: 794895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
    Swinburn BA; Carmichael HE; Wilson MR
    Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1033-40. PubMed ID: 8923161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychological and metabolic effects of dietary carbohydrates and dexfenfluramine during a low-energy diet in obese women.
    Kogon MM; Kräuchi K; Van der Velde P; Van der Werf H; Keller U
    Am J Clin Nutr; 1994 Oct; 60(4):488-93. PubMed ID: 8092082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of obesity with fenfluramine.
    Persson I; Andersen U; Deckert T
    Eur J Clin Pharmacol; 1973 Aug; 6(2):93-7. PubMed ID: 4588854
    [No Abstract]   [Full Text] [Related]  

  • 17. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT; Richman RM; Steinbeck KS; Caterson ID
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of prolonged fenfluramine administration in obese and nonobese mice.
    Carr RH; Ipaktchi M; Thenen SW
    Proc Soc Exp Biol Med; 1977 Jan; 154(1):116-20. PubMed ID: 320596
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
    Weintraub M; Sundaresan PR; Madan M; Schuster B; Balder A; Lasagna L; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):586-94. PubMed ID: 1587072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue ascorbic acid, fenfluramine, and changes in fat metabolism.
    Odumosu A; Wilson CW
    Int J Obes; 1979; 3(2):123-31. PubMed ID: 528124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.